5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial

被引:105
作者
Hage, M
Siersema, PD
van Dekken, H
Steyerberg, EW
Haringsma, J
van de Vrie, W
Grool, TE
van Veen, RLP
Sterenborg, HJCM
Kuipers, EJ
机构
[1] Erasmus MC Univ, Dept Gastroenterol & Hepatol, Med Ctr, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC Univ, Dept Pathol, Med Ctr, NL-3000 CA Rotterdam, Netherlands
[3] Erasmus MC Univ, Dept Publ Hlth, Med Ctr, NL-3000 CA Rotterdam, Netherlands
[4] Erasmus MC Univ, Dept Radiat Oncol, Med Ctr, Photodynam Therapy & Opt Spect Res Program, NL-3000 CA Rotterdam, Netherlands
关键词
D O I
10.1136/gut.2003.028860
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Photochemical and thermal methods are used for ablating Barrett's oesophagus (BO). The aim of this study was to compare 5-aminolevulinic acid induced photodynamic therapy (ALA-PDT) with argon plasma coagulation (APC) with respect to complete reversal of BO. Methods: Patients with BO (32 no dysplasia and eight low grade dysplasia) were randomised to one of three treatments: (a) ALA-PDT as a single dose of 100 J/cm(2) at four hours (PDT100; n = 13); (b) ALA-PDT as a fractionated dose of 20 and 100 J/cm(2) at one and four hours, respectively (PDT20+ 100; n = 13); or ( c) APC at a power setting of 65 W in two sessions (APC; n = 14). If complete elimination of BO was not achieved by the designated treatment, the remaining BO was treated by a maximum of two sessions of APC. Results: Mean endoscopic reduction of BO at six weeks was 51% (range 20-100%) in the PDT100 group, 86% (range 0-100%) in the PDT20+ 100 group, and 93% (range 40-100%) in the APC group (PDT100 v PDT20+ 100, p<0.005; PDT100 v APC, p<0.005; and PDT20+ 100 v APC, NS) with histologically complete ablation in 1/13 (8%) patients in the PDT100 group, 4/12 (33%) in the PDT20+ 100 group, and 5/14 (36%) in the APC group (NS). Remaining BO was additionally treated with APC in 23/40 (58%) patients. Histological examination at 12 months revealed complete ablation in 9/11 (82%) patients in the PDT100 group, in 9/10 (90%) patients in the PDT20+ 100 group, and in 8/12 (67%) patients in the APC group (NS). At 12 months, no dysplasia was detected. Side effects (that is, pain ( p<0.01), and nausea and vomiting (p<0.05)) and elevated liver transaminases (p<0.01) were more common after PDT than APC therapy. One patient died three days after treatment with PDT, presumably from cardiac arrhythmia. Conclusion: APC alone or ALA-PDT in combination with APC can lead to complete reversal of Barrett's epithelium in at least two thirds of patients when administered in multiple treatment sessions. As the goal of treatment should be complete reversal of Barrett's epithelium, we do not recommend these techniques for the prophylactic ablation of BO.
引用
收藏
页码:785 / 790
页数:6
相关论文
共 33 条
[1]   Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial [J].
Ackroyd, R ;
Brown, NJ ;
Davis, MF ;
Stephenson, TJ ;
Marcus, SL ;
Stoddard, CJ ;
Johnson, AG ;
Reed, MWR .
GUT, 2000, 47 (05) :612-617
[2]   Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo [J].
Babillas, P ;
Schacht, V ;
Liebsch, G ;
Wolfbeis, OS ;
Landthaler, M ;
Szeirinies, RM ;
Abels, C .
BRITISH JOURNAL OF CANCER, 2003, 88 (09) :1462-1469
[3]   Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium [J].
Basu, KK ;
Pick, B ;
Bale, R ;
West, KP ;
de Caestecker, JS .
GUT, 2002, 51 (06) :776-780
[4]  
Dolmans DEJGJ, 2002, CANCER RES, V62, P4289
[5]   Biomarker studies in reversed Barrett's esophagus [J].
Garewal, H ;
Ramsey, L ;
Sharma, P ;
Kraus, K ;
Sampliner, R ;
Fass, R .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (10) :2829-2833
[6]   Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid [J].
Gossner, L ;
Stolte, M ;
Sroka, R ;
Rick, K ;
May, A ;
Hahn, EG ;
Ell, C .
GASTROENTEROLOGY, 1998, 114 (03) :448-455
[7]   Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid [J].
Hinnen, P. ;
de Rooij, F. W. M. ;
Terlouw, E. M. ;
Edixhoven, A. ;
van Dekken, H. ;
van Hillegersberg, R. ;
Tilanus, H. W. ;
Wilson, J. H. P. ;
Siersema, P. D. .
BRITISH JOURNAL OF CANCER, 2000, 83 (04) :539-543
[8]  
Hinnen P, 2002, CELL MOL BIOL, V48, P903
[9]   Barrett's metaplasia [J].
Jankowski, JA ;
Harrison, RF ;
Perry, I ;
Balkwill, F ;
Tselepis, C .
LANCET, 2000, 356 (9247) :2079-2085
[10]   Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression [J].
Kahaleh, M ;
Van Laethem, JL ;
Nagy, N ;
Cremer, M ;
Devière, J .
ENDOSCOPY, 2002, 34 (12) :950-955